<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Antioxidants (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Antioxidants (Basel)</journal-id><journal-id journal-id-type="pmc-domain-id">2840</journal-id><journal-id journal-id-type="pmc-domain">antiox</journal-id><journal-id journal-id-type="publisher-id">antioxidants</journal-id><journal-title-group><journal-title>Antioxidants</journal-title></journal-title-group><issn pub-type="epub">2076-3921</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12024012</article-id><article-id pub-id-type="pmcid-ver">PMC12024012.1</article-id><article-id pub-id-type="pmcaid">12024012</article-id><article-id pub-id-type="pmcaiid">12024012</article-id><article-id pub-id-type="pmid">40298799</article-id><article-id pub-id-type="doi">10.3390/antiox14040474</article-id><article-id pub-id-type="publisher-id">antioxidants-14-00474</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Sucralose Promotes Benzo(a)Pyrene-Induced Renal Toxicity in Mice by Regulating P-glycoprotein</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0007-5701-1797</contrib-id><name name-style="western"><surname>Hu</surname><given-names initials="J">Jun</given-names></name><xref rid="af1-antioxidants-14-00474" ref-type="aff">1</xref><xref rid="fn1-antioxidants-14-00474" ref-type="author-notes">&#8224;</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Feng</surname><given-names initials="J">Ji</given-names></name><xref rid="af1-antioxidants-14-00474" ref-type="aff">1</xref><xref rid="fn1-antioxidants-14-00474" ref-type="author-notes">&#8224;</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0009-0266-4517</contrib-id><name name-style="western"><surname>Bai</surname><given-names initials="Y">Yan</given-names></name><xref rid="af1-antioxidants-14-00474" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yao</surname><given-names initials="ZS">Zhi-Sheng</given-names></name><xref rid="af1-antioxidants-14-00474" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wu</surname><given-names initials="XY">Xiao-Yu</given-names></name><xref rid="af1-antioxidants-14-00474" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-8411-2610</contrib-id><name name-style="western"><surname>Hong</surname><given-names initials="XY">Xin-Yu</given-names></name><xref rid="af2-antioxidants-14-00474" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-6056-3196</contrib-id><name name-style="western"><surname>Lu</surname><given-names initials="GD">Guo-Dong</given-names></name><xref rid="af1-antioxidants-14-00474" ref-type="aff">1</xref><xref rid="c1-antioxidants-14-00474" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-6268-7886</contrib-id><name name-style="western"><surname>Xue</surname><given-names initials="K">Kun</given-names></name><xref rid="af1-antioxidants-14-00474" ref-type="aff">1</xref><xref rid="c1-antioxidants-14-00474" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Plotnikov</surname><given-names initials="EY">Egor Yu.</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-antioxidants-14-00474"><label>1</label>School of Public Health, Fudan University, Shanghai 200032, China; <email>22211020134@m.fudan.edu.cn</email> (J.H.); <email>feng_ji@fudan.edu.cn</email> (J.F.); <email>23211020112@m.fudan.edu.cn</email> (Y.B.); <email>24111020094@m.fudan.edu.cn</email> (Z.-S.Y.); <email>24211020227@m.fudan.edu.cn</email> (X.-Y.W.)</aff><aff id="af2-antioxidants-14-00474"><label>2</label>Shanghai Municipal Center for Disease Control and Prevention, Shanghai 200336, China; <email>hongxinyu@scdc.sh.cn</email></aff><author-notes><corresp id="c1-antioxidants-14-00474"><label>*</label>Correspondence: <email>lugd@fudan.edu.cn</email> (G.-D.L.); <email>xuekun@shmu.edu.cn</email> (K.X.); Tel.: +86-21-54237707 (G.-D.L.); +86-21-54237229 (K.X.)</corresp><fn id="fn1-antioxidants-14-00474"><label>&#8224;</label><p>These authors contribute equally to the work.</p></fn></author-notes><pub-date pub-type="epub"><day>16</day><month>4</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>4</month><year>2025</year></pub-date><volume>14</volume><issue>4</issue><issue-id pub-id-type="pmc-issue-id">487271</issue-id><elocation-id>474</elocation-id><history><date date-type="received"><day>10</day><month>3</month><year>2025</year></date><date date-type="rev-recd"><day>12</day><month>4</month><year>2025</year></date><date date-type="accepted"><day>13</day><month>4</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>16</day><month>04</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>26</day><month>04</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-04-30 13:25:37.810"><day>30</day><month>04</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="antioxidants-14-00474.pdf"/><abstract><p>Background: Sucralose and benzo(a)pyrene (B[<italic toggle="yes">a</italic>]P) are widespread foodborne substances known to harm human health. However, the effects of their combined exposure on kidney function remain unclear. This study aimed to investigate the mechanisms by which sucralose and B[<italic toggle="yes">a</italic>]P induce kidney injury through P-glycoprotein (PGP/ABCB1), a crucial protein involved in cellular detoxification. Methods: C57BL/6N mice were co-treated with sucralose and B[<italic toggle="yes">a</italic>]P for 90 days to evaluate their impact on kidney histopathology and function. In vitro experiments assessed cell viability, reactive oxygen species (ROS) levels, and B[<italic toggle="yes">a</italic>]P accumulation by flow cytometry. Molecular docking and cellular thermal shift assay (CETSA) were used to determine the binding affinity of sucralose to PGP. Furthermore, PCR, Western blotting, and immunohistochemistry were performed to analyze the expression of PGP and its upstream transcription factors. Results: Ninety days of co-exposure to sucralose and B[<italic toggle="yes">a</italic>]P significantly exacerbated renal dysfunction in mice, as evidenced by the elevated level of serum creatinine and urea nitrogen, which could be reverted by ROS scavenger N-acetyl cysteine (NAC). In vitro, sucralose promoted cellular accumulation of B[<italic toggle="yes">a</italic>]P, consequently enhancing B[<italic toggle="yes">a</italic>]P-induced cell growth inhibition and ROS production. Consistently, B[<italic toggle="yes">a</italic>]P accumulation was enhanced by PGP knockdown in both HK2 and HEK-293 cells. Mechanistically, sucralose can directly bind to PGP, competitively inhibiting its efflux capacity and increasing intracellular B[<italic toggle="yes">a</italic>]P retention. Prolonged co-exposure further downregulated PGP expression, possibly through the reductions of its transcriptional regulators (<italic toggle="yes">PXR</italic>, <italic toggle="yes">NRF2</italic>, and <italic toggle="yes">NF-&#954;B</italic>). Conclusions: Co-exposure to sucralose and B[<italic toggle="yes">a</italic>]P exacerbates renal injury by impairing PGP function. Mechanistically, sucralose inhibits PGP activity, resulting in the accumulation of B[<italic toggle="yes">a</italic>]P within renal cells. This accumulation triggers oxidative stress and inhibits cell growth, which demonstrates that sucralose potentiates B[<italic toggle="yes">a</italic>]P-induced nephrotoxicity by directly inhibiting PGP-mediated detoxification pathways, thus underscoring the critical need to evaluate toxicity risks associated with combined exposure to these compounds.</p></abstract><kwd-group><kwd>sucralose</kwd><kwd>P-glycoprotein (PGP/ABCB1)</kwd><kwd>benzo(a)pyrene</kwd><kwd>oxidative stress</kwd><kwd>nephrotoxicity</kwd></kwd-group><funding-group><award-group><funding-source>Shanghai Three-Year Action Plan for Strengthening the Public Health System Research</funding-source><award-id>GWVI-11.1-41</award-id></award-group><award-group><funding-source>Postdoctoral Fellowship Program of CPSF</funding-source><award-id>GZC20230466</award-id></award-group><funding-statement> This work was supported by the Shanghai Three-Year Action Plan for Strengthening the Public Health System Research (2023&#8211;2025) on Integrated Strategies for Traceability and Identification of Chemicals with Health Impacts and Their Human Hazard Assessment (GWVI-11.1-41) and the Postdoctoral Fellowship Program of CPSF (GZC20230466).</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-antioxidants-14-00474"><title>1. Introduction</title><p>Non-nutritive artificial sweeteners, widely adopted as calorie-free sugar alternatives, were ubiquitously incorporated into beverages, dairy products, and processed food formulations to meet consumer demand for reduced caloric intake [<xref rid="B1-antioxidants-14-00474" ref-type="bibr">1</xref>]. Notably, the global market for artificial sweeteners expanded rapidly from USD 84 billion in 2014 to USD 1.11 trillion by 2020 [<xref rid="B2-antioxidants-14-00474" ref-type="bibr">2</xref>]. Among non-nutritive artificial sweeteners, aspartame remains the most extensively utilized (18,500 metric tons annually), followed by saccharin (9700 metric tons), acesulfame potassium (6800 metric tons), and sucralose (3300 metric tons) [<xref rid="B3-antioxidants-14-00474" ref-type="bibr">3</xref>].</p><p>Despite the establishment of Acceptable Daily Intake (ADI) standards for commonly used sweeteners by the Joint FAO/WHO Expert Committee on Food Additives (JECFA), a recent surveillance study reveals widespread non-compliance, including off-label applications, excessive dosing, and misuse [<xref rid="B4-antioxidants-14-00474" ref-type="bibr">4</xref>,<xref rid="B5-antioxidants-14-00474" ref-type="bibr">5</xref>]. The detection of artificial sweeteners and their metabolites in groundwater across multiple nations has raised concerns regarding their environmental persistence and potential toxicological impacts [<xref rid="B3-antioxidants-14-00474" ref-type="bibr">3</xref>]. Of particular concern is sucralose because of its high metabolic stability. Pharmacokinetic studies indicate that only 10&#8211;20% of ingested sucralose is excreted renally, with merely 2% existing as glucuronide conjugates, suggesting its prolonged systemic retention and bioaccumulation risks [<xref rid="B6-antioxidants-14-00474" ref-type="bibr">6</xref>].</p><p>Benzo[a]pyrene (B[<italic toggle="yes">a</italic>]P), a representative polycyclic aromatic hydrocarbon (PAH), is commonly found in the environment and generated through routine human activities [<xref rid="B7-antioxidants-14-00474" ref-type="bibr">7</xref>]. It is primarily produced during the incomplete combustion of organic matter. Human exposure to B[<italic toggle="yes">a</italic>]P is almost unavoidable; it can occur through the ingestion of grilled foods, contaminated water, and inhalation of cigarette smoke [<xref rid="B8-antioxidants-14-00474" ref-type="bibr">8</xref>]. The accumulation of B[<italic toggle="yes">a</italic>]P in the body can lead to significant toxicological effects, including DNA damage [<xref rid="B9-antioxidants-14-00474" ref-type="bibr">9</xref>] and carcinogenesis [<xref rid="B10-antioxidants-14-00474" ref-type="bibr">10</xref>]. Additionally, B[<italic toggle="yes">a</italic>]P exposure has been shown to increase serum urea and creatinine levels, as well as induce severe histopathological changes in the kidney [<xref rid="B11-antioxidants-14-00474" ref-type="bibr">11</xref>]. Although both sucralose and B[<italic toggle="yes">a</italic>]P are commonly encountered in daily life, research on their combined exposure and potential synergistic effects remains limited.</p><p>P-glycoprotein (PGP) is an ATP-dependent transmembrane transporter predominantly expressed in excretory organs, including the kidney. It plays a critical role in the active efflux of intracellular xenobiotics, including environmental toxins and chemotherapeutic agents, thereby contributing to the maintenance of cellular homeostasis [<xref rid="B12-antioxidants-14-00474" ref-type="bibr">12</xref>,<xref rid="B13-antioxidants-14-00474" ref-type="bibr">13</xref>,<xref rid="B14-antioxidants-14-00474" ref-type="bibr">14</xref>]. Dysfunction of PGP can lead to the abnormal accumulation of B[<italic toggle="yes">a</italic>]P in human breast cancer cells [<xref rid="B15-antioxidants-14-00474" ref-type="bibr">15</xref>]. A recent study revealed that sucralose may disrupt xenobiotic metabolism by interfering with cellular drug efflux systems [<xref rid="B16-antioxidants-14-00474" ref-type="bibr">16</xref>]. However, to date, there have been no reported studies investigating the combined effects of benzo[a]pyrene (B[<italic toggle="yes">a</italic>]P) and sucralose on normal tissues. The potential synergistic toxicity of these two compounds, particularly in the context of renal health, remains largely unexplored.</p><p>Therefore, this study aims to fill this gap by evaluating the combined effects of sucralose and B[<italic toggle="yes">a</italic>]P on kidney function. We thus conducted a 90-day subchronic exposure experiment in mice, accompanied by in vitro cellular experiments, to investigate the renal toxicity and underlying mechanisms associated with co-exposure to these substances. Furthermore, we aim to examine how sucralose influences the toxicological effects of B[<italic toggle="yes">a</italic>]P, particularly in identifying potential molecular pathways involved in their combined impact on kidney health.</p></sec><sec id="sec2-antioxidants-14-00474"><title>2. Materials and Methods </title><sec id="sec2dot1-antioxidants-14-00474"><title>2.1. Animal Experiments</title><p>Seventy male C57BL/6N mice (20.1 &#177; 1 g) were purchased from Viton Lever (Beijing, China). Animals were housed in cages under controlled temperature (23 &#177; 1 &#176;C) and relative humidity (50&#8211;55%) in a light/dark (12 h/12 h) cycle with ad libitum access to food and drinking water. All experiments were ethically approved by the Department of Laboratory Animal Science, Fudan University (approval number: 202409018S) and performed in accordance with the Association for Assessment and Accreditation of Laboratory Animal Care guidelines. After one week of acclimatization, the mice were randomly divided into seven groups (<italic toggle="yes">n</italic> = 10 per group), including control group (corn oil), the low-concentration sucralose group (5 mg/kg sucralose), the high-concentration sucralose group (15 mg/kg sucralose), the B[<italic toggle="yes">a</italic>]P alone group (50 mg/kg B[<italic toggle="yes">a</italic>]P), the combination group of low sucralose and B[<italic toggle="yes">a</italic>]P (5 mg/kg sucralose + 50 mg/kg B[<italic toggle="yes">a</italic>]P), the combination group of high sucralose and B[<italic toggle="yes">a</italic>]P (15 mg/kg sucralose + 50 mg/kg B[<italic toggle="yes">a</italic>]P), and the combination group of high sucralose and B[<italic toggle="yes">a</italic>]P plus NAC (100 mg/kg NAC). B[<italic toggle="yes">a</italic>]P was dissolved in corn oil and given by gavage every other day for 3 months, as described in previous studies [<xref rid="B17-antioxidants-14-00474" ref-type="bibr">17</xref>,<xref rid="B18-antioxidants-14-00474" ref-type="bibr">18</xref>]. The B[<italic toggle="yes">a</italic>]P dosing regimen was established through the integration of published toxicological data and regulatory safety guidelines, where literature-derived murine toxicity models employing 50&#8211;100 mg/kg doses [<xref rid="B19-antioxidants-14-00474" ref-type="bibr">19</xref>,<xref rid="B20-antioxidants-14-00474" ref-type="bibr">20</xref>] were reconciled with human occupational exposure thresholds (2.0 mg/kg) [<xref rid="B21-antioxidants-14-00474" ref-type="bibr">21</xref>] through the application of the U.S. EPA-mandated 100-fold uncertainty factor for interspecies extrapolation. In the present study, high and low doses of sucralose were calculated through body surface area conversion, strictly adhering to the ADI values established by the U.S. FDA and WHO/JECFA. Consistently, mice received sucralose via drinking water at concentrations of 0.72 mg/mL and 0.17 mg/mL in a previous study [<xref rid="B22-antioxidants-14-00474" ref-type="bibr">22</xref>]. This dosing regimen ensured cumulative exposure over the 10-week experimental period closely approximated the human ADI guidelines. The amount of water consumed was recorded. Mice were sacrificed at the end of the experiment, then their blood and kidneys were collected. A portion of the kidneys was fixed in 4% paraformaldehyde for histopathological examination, and the remaining tissues were rinsed with saline and stored in liquid nitrogen until further use.</p></sec><sec id="sec2dot2-antioxidants-14-00474"><title>2.2. Antibodies, Chemicals and Reagents</title><p>PGP (#22336-1-AP), GAPDH (#81640-5-RR) and Alpha Tubulin (#11224-1-AP) were purchased from Proteintech; while <italic toggle="yes">&#947;</italic>-H2AX (#9718); Caspase-3 (#9661); Bax (#2772); Bcl-2(#D17C4) were bought from Cell Signaling Technology (Danvers, MA, USA). The IHC experiments were carried out as before [<xref rid="B23-antioxidants-14-00474" ref-type="bibr">23</xref>]. Sucralose (#S107614), benzo(a)pyrene (#B110854), verapamil hydrochloride (#V111249), N-acetylcysteine (#A105420), and corn oil (#C116023) were purchased from Aladdin (Shanghai, China).</p></sec><sec id="sec2dot3-antioxidants-14-00474"><title>2.3. Cell Culture and Cell Viability Assay</title><p>The HEK-293 and HK2 from the National Collection of Authenticated Cell Cultures were cultured in Dulbecco&#8217;s Modified Eagle Medium (DMEM) or DMEM/F12 50/50, respectively, and supplemented with 10% FBS (Biovision, Milpitas, CA, USA), 1% penicillin/streptomycin. Cells were cultured in a saturated humidity incubator at 37 &#176;C, 5% CO<sub>2</sub>. Cell viability was assessed using a propidium iodide (#P4170, Sigma-Aldrich, St. Louis, MI, USA) exclusion assay in a flow cytometer (CytoFLEX, Beckman, Brea, CA, USA), as previously described [<xref rid="B23-antioxidants-14-00474" ref-type="bibr">23</xref>].</p></sec><sec id="sec2dot4-antioxidants-14-00474"><title>2.4. Biochemical Analysis</title><p>Serum was collected from mice by ophthalmoplegia, then centrifuged at 1000&#215; <italic toggle="yes">g</italic> for 10 min. Serum creatinine (CRE) and urea nitrogen (BUN) were measured using Creatinine assay test kit (#D799853, Sangon Biotech, Shanghai, China) or urea nitrogen assay kit (#D799850, Sangon Biotech), respectively.</p></sec><sec id="sec2dot5-antioxidants-14-00474"><title>2.5. Histology Staining</title><p>Renal tissues were sliced into 4 &#956;m-thick sections and stained with hematoxylin and eosin (H&amp;E) or periodic acid-Schiff (PAS). Tissue damage was quantified in a blinded manner. Renal tissue damage was scored according to the percentage of damaged tubules: 0, no damage; 1, less than 25% damage; 2, 25&#8211;50% damage; 3, 50&#8211;75% damage; 4, more than 75% damage [<xref rid="B24-antioxidants-14-00474" ref-type="bibr">24</xref>]. The criteria for renal tubular injury include detachment of renal tubular epithelial cells, atrophic flattening of renal proximal tubules, and crumpled and deformed glomeruli.</p></sec><sec id="sec2dot6-antioxidants-14-00474"><title>2.6. Cellular Oxidative Stress Assay</title><p>HEK-293 cells or HK2 cells were seeded in 6-well plates at a density of 3 &#215; 10<sup>5</sup> cells per well and cultured until reaching approximately 60% confluency. Subsequently, the cells were treated with sucralose alone, B[<italic toggle="yes">a</italic>]P alone, or the combination as indicated for 24 h and 72 h. The positive control group was conducted according to the manuals of the reactive oxygen species detection kit (#S0033S, Beyotime Biotechnology, Shanghai, China) and the mitochondrial superoxide detection kit (#S0061S, Beyotime Biotechnology). The contents of reactive oxygen species in the cells of each group were detected by an Inverted Fluorescence Microscope (IX81, OLYMPUS, Tokyo, Japan) and flow cytometry (CytoFLEX, BECKMAN COULTER, Brea, CA, USA).</p></sec><sec id="sec2dot7-antioxidants-14-00474"><title>2.7. B[a]P Accumulation and Efflux Assay</title><p>Intracellular accumulation or efflux of B[<italic toggle="yes">a</italic>]P was examined by flow cytometry. Briefly, HEK-293 or HK2 cells were seeded in clear 12-well plates at a density of 2.5 &#215; 10<sup>5</sup> cells per well. For B[<italic toggle="yes">a</italic>]P accumulation assay, cells were treated as indicated and collected every 2 h for quantitative analysis of intracellular B[<italic toggle="yes">a</italic>]P levels by flow cytometry. For B[<italic toggle="yes">a</italic>]P efflux assay, cells were initially exposed to 2 &#956;M B[<italic toggle="yes">a</italic>]P for 12 h. After a gentle wash with a complete medium, the culture medium was carefully replaced with a fresh complete medium with or without sucralose (10 &#956;M). Cells were then incubated under light-protected conditions. The intracellular B[<italic toggle="yes">a</italic>]P concentrations were finally quantified via flow cytometry at 2 h intervals.</p></sec><sec id="sec2dot8-antioxidants-14-00474"><title>2.8. Cell Transient Transfection (PGP siRNA)</title><p>For transient knockdown, siRNAs (Sangon Biotech) against negative control (NC-si) or PGP (PGP-si1, PGP-si2, PGP-si3) were given to cells with the aid of Lipofectamine RNAiMAX (Thermo Fisher, Waltham, MA, USA). The nucleotide sequence of si-RNAs is summarized in <xref rid="antioxidants-14-00474-t001" ref-type="table">Table 1</xref>.</p></sec><sec id="sec2dot9-antioxidants-14-00474"><title>2.9. Molecular Docking</title><p>The cryo-electron microscopy structure of nanodisk reconstituted drug-free human PGP/ABCB1 was retrieved from the Protein Data Bank (PDB #7A65) [<xref rid="B25-antioxidants-14-00474" ref-type="bibr">25</xref>]. Hydrogen atoms and Gasteiger charges were added according to the AutoDock Vina documentation (version 1.2.0) [<xref rid="B26-antioxidants-14-00474" ref-type="bibr">26</xref>] using the prepare receptor script from the ADFR suite [<xref rid="B27-antioxidants-14-00474" ref-type="bibr">27</xref>]. Reference 3D models of sucralose, verapamil, and quinidine were retrieved from the Pubchem database, downloaded in sdf format, converted to pdb format using OpenBabel (version 2.4.1), and converted to pdbqt files using Autodocking (version 1.5.7). The pdbqt files of receptors and ligandswere used for docking experiments with AutoDock Vina [<xref rid="B26-antioxidants-14-00474" ref-type="bibr">26</xref>]. We used the Orientation of Proteins in Membranes (OPM) database [<xref rid="B28-antioxidants-14-00474" ref-type="bibr">28</xref>] (model 7a65.pdb) to adjust the coordinates and dimensions of the docking frames in the transmembrane region of the receptor. Vina 1.2 was run with an exhaustive parameter of 32, and docking was simulated 50 times per experiment. For each ligand, the corresponding binding poses on the receptor were examined and checked for consistency with the experimental data. The best binding poses associated with Vina&#8217;s built-in scoring function were then selected for presentation in this manuscript. PGP and docked ligands were visualized with PyMOL (version 4.6.0).</p></sec><sec id="sec2dot10-antioxidants-14-00474"><title>2.10. Western Blotting Assay</title><p>Cells were collected and lysed on ice utilizing RIPA lysate. After sufficient lysis, the cells were centrifuged at 12,000&#215; <italic toggle="yes">g</italic> for 10 min at 4 &#176;C, and the proteins of each treatment group were quantified using the BCA Protein Concentration Assay Kit (#P0012, Beyotime Biotechnology). Proteins were separated by SDS-PAGE and transferred to PVDF membranes (#ISEQ00010, Millipore, Bedford, MA, USA). After sealing the non-specific sites with 5% skimmed milk, the membranes were incubated overnight at 4 &#176;C with the corresponding primary antibodies, followed by 1&#8211;2 h incubation with horseradish peroxidase-coupled secondary antibodies. Color development was performed using chemiluminescent reagents, and the intensity of protein bands was quantified using ImageJ software (version 1.52a) (NIH, Bethesda, MD, USA).</p></sec><sec id="sec2dot11-antioxidants-14-00474"><title>2.11. RNA Extraction, cDNA Synthesis, and RT-qPCR</title><p>Total RNA was extracted from treated cells by RNAiso Plus (#9019, Takara, Beijing, China) according to manufacturer&#8217;s instructions. cDNA synthesis was performed with the PrimeScript&#8482; RT Master Mix (#RR036A, Takara), followed by qPCR analysis using gene-specific primers. Sequence-specific amplification was detected using TB Green<sup>&#174;</sup> Premix Ex Taq&#8482; II FAST qPCR (#RR830A, Takara) on the CFX Opus Real-Time PCR System (Bio-Rad, Hercules, CA, USA). Primers were obtained from Sangon Biotech (Shanghai, China) and summarized in <xref rid="antioxidants-14-00474-t002" ref-type="table">Table 2</xref>.</p></sec><sec id="sec2dot12-antioxidants-14-00474"><title>2.12. Cellular Thermal Shift Assay (CETSA)</title><p>The HK2 cell disruption solution was first prepared, divided into three groups by adding sucralose (10 &#956;M), verapamil (10 &#956;M) and PBS, and incubated at 37 &#176;C for 30 min. The protein of each treatment group was then dispensed in 80 &#956;L/tube into 10 PCR tubes and heated for 3 min at different temperatures (37 &#176;C, 41 &#176;C, 43 &#176;C, 47 &#176;C, 50 &#176;C, 53 &#176;C, 57 &#176;C, 60 &#176;C, 63 &#176;C, 67 &#176;C), and cooled at room temperature. Finally, the PGP protein expression levels were detected by Western blotting.</p></sec><sec id="sec2dot13-antioxidants-14-00474"><title>2.13. Statistical Analyses</title><p>Data were analyzed using GraphPad Prism software (version 9.5.0), and all data were expressed as mean &#177; standard deviation from at least three independent experiments. One-way ANOVA with Duncan&#8217;s test was used to assess significant differences between means, with statistical significance set at <italic toggle="yes">p</italic> &lt; 0.05.</p></sec></sec><sec sec-type="results" id="sec3-antioxidants-14-00474"><title>3. Results</title><sec id="sec3dot1-antioxidants-14-00474"><title>3.1. Sucralose Enhanced B[a]P-Induced Subchronic Kidney Injury</title><p>To explore the effect of combined sucralose and B[<italic toggle="yes">a</italic>]P exposure on renal injury in mice, we administered B[<italic toggle="yes">a</italic>]P with or without sucralose treatment to mice over a period of 90 days. Renal damage was assessed by measuring blood creatinine and urea nitrogen levels and examining kidney tissue pathology. The experimental results showed that renal function abnormality was unobservable in all groups at 30 days of treatment (<xref rid="app1-antioxidants-14-00474" ref-type="app">Figure S1A,B</xref>) and at 90 days of sucralose alone treatment. However, after 90 days of treatment, B[<italic toggle="yes">a</italic>]P treatment alone caused renal damage, as evidenced by elevated serum creatinine and blood urea nitrogen levels (<xref rid="antioxidants-14-00474-f001" ref-type="fig">Figure 1</xref>A,B) and significant pathological changes in tubular injury (<xref rid="antioxidants-14-00474-f001" ref-type="fig">Figure 1</xref>C,D). Notably, high-dose sucralose further exacerbated B[<italic toggle="yes">a</italic>]P-induced renal damage. In contrast, the ROS scavenger NAC attenuated the renal injury induced by the combined treatment (<xref rid="antioxidants-14-00474-f001" ref-type="fig">Figure 1</xref>A,D).</p></sec><sec id="sec3dot2-antioxidants-14-00474"><title>3.2. Sucralose Sensitized B[a]P-Induced Cell Growth Inhibition and ROS Production</title><p>To investigate the mechanisms underlying the enhanced renal injury by the combined treatment, we selected human renal tubular epithelial HK2 cells and human embryonic kidney HEK-293 cells for in vitro experiments. Our preliminary cytotoxicity assay indicated that sucralose, within the concentration range of 2.5&#8211;100 &#956;M, exerted minimal effects on cell proliferation (<xref rid="app1-antioxidants-14-00474" ref-type="app">Figure S2</xref>). Considering that the plasma concentration of sucralose in adults ranges from approximately 0.92 to 3.92 &#956;M [<xref rid="B29-antioxidants-14-00474" ref-type="bibr">29</xref>] and its known tendency to accumulate in renal tissues, we selected 10 &#956;M sucralose for subsequent in vitro experiments. Likewise, B[<italic toggle="yes">a</italic>]P was used at 20 &#956;M, a concentration commonly employed in in vitro studies [<xref rid="B30-antioxidants-14-00474" ref-type="bibr">30</xref>,<xref rid="B31-antioxidants-14-00474" ref-type="bibr">31</xref>,<xref rid="B32-antioxidants-14-00474" ref-type="bibr">32</xref>]. Although there were no significant changes within 24 h, sucralose markedly sensitized B[<italic toggle="yes">a</italic>]P-induced cell growth inhibition in both HK2 and HEK-293 cells (<xref rid="antioxidants-14-00474-f002" ref-type="fig">Figure 2</xref>A,B). Since antioxidant NAC reduced renal injury induced by the combined treatment in mice (<xref rid="antioxidants-14-00474-f001" ref-type="fig">Figure 1</xref>), we examined the ROS generation by sucralose, B[<italic toggle="yes">a</italic>]P, and their combination in vitro. The results confirmed that sucralose could increase generations of both B[<italic toggle="yes">a</italic>]P-induced general ROS (<xref rid="antioxidants-14-00474-f002" ref-type="fig">Figure 2</xref>C,D) and mitochondrial-ROS levels (<xref rid="antioxidants-14-00474-f002" ref-type="fig">Figure 2</xref>E). Consistently, the combined treatment markedly decreased the expression of major antioxidant genes, including <italic toggle="yes">SOD2</italic>, <italic toggle="yes">CAT</italic>, <italic toggle="yes">GSS</italic>, and <italic toggle="yes">GPX1</italic> (<xref rid="antioxidants-14-00474-f002" ref-type="fig">Figure 2</xref>F). Taken together, these results suggest that sucralose could exacerbate B[<italic toggle="yes">a</italic>]P-induced cell growth inhibition and ROS production.</p></sec><sec id="sec3dot3-antioxidants-14-00474"><title>3.3. Sucralose Promotes B[a]P Intracellular Accumulation and Retention in Renal Cells</title><p>Next, we tested whether sucralose influences the intracellular accumulation of B[<italic toggle="yes">a</italic>]P in vitro. The combined treatment significantly caused a higher level of B[<italic toggle="yes">a</italic>]P accumulation in both HK2 and HEK-293 cells, compared to B[<italic toggle="yes">a</italic>]P alone treatment (<xref rid="antioxidants-14-00474-f003" ref-type="fig">Figure 3</xref>A,B). Since cellular efflux contributes to B[<italic toggle="yes">a</italic>]P accumulation, we next assessed B[<italic toggle="yes">a</italic>]P efflux. After cells were treated with B[<italic toggle="yes">a</italic>]P alone for 12 h, the culture medium was replaced with sucralose, and then the intracellular level of B[<italic toggle="yes">a</italic>]P was determined at a 2 h interval. Notably, the addition of sucralose could reduce B[<italic toggle="yes">a</italic>]P efflux efficiency, as the median duration of B[<italic toggle="yes">a</italic>]P retention was increased from 9.48 &#177; 0.01 h to 13.55 &#177; 0.01 h in HK2 cells (<xref rid="antioxidants-14-00474-f003" ref-type="fig">Figure 3</xref>C) and 6.01 &#177; 0.11 h to 11.29 &#177; 0.02 h in HEK-293 cells (<xref rid="antioxidants-14-00474-f003" ref-type="fig">Figure 3</xref>D). Therefore, these findings implied that sucralose might inhibit B[<italic toggle="yes">a</italic>]P efflux in renal cells.</p></sec><sec id="sec3dot4-antioxidants-14-00474"><title>3.4. Knockdown of PGP Protein Further Promotes Sucralose-Induced B[a]P Accumulation</title><p>In order to examine whether sucralose-promoted B[<italic toggle="yes">a</italic>]P accumulation is related to cellular efflux function, we further determined the role of PGP (<xref rid="antioxidants-14-00474-f004" ref-type="fig">Figure 4</xref>A), a transmembrane protein capable of effluxing B[<italic toggle="yes">a</italic>]P. As expected, knockdown of PGP promoted B[<italic toggle="yes">a</italic>]P accumulation (<xref rid="antioxidants-14-00474-f004" ref-type="fig">Figure 4</xref>B) and reduced B[<italic toggle="yes">a</italic>]P efflux when compared with the NC-si treatment group (<xref rid="antioxidants-14-00474-f004" ref-type="fig">Figure 4</xref>C, as the median of retention increased from 8 h in the NC-si group to 11 in PGP-si2 or 13 h in PGP-si3 group). Moreover, PGP knockdown further enhanced sucralose-induced B[<italic toggle="yes">a</italic>]P accumulation (<xref rid="antioxidants-14-00474-f004" ref-type="fig">Figure 4</xref>D) and retention (<xref rid="antioxidants-14-00474-f004" ref-type="fig">Figure 4</xref>E, comparing 12 h in the NC-si-sucralose group to 15 or 18 h in the NGP-si + sucralose groups).</p></sec><sec id="sec3dot5-antioxidants-14-00474"><title>3.5. Sucralose Inhibits B[a]P Efflux by Binding Specifically to PGP</title><p>To investigate whether sucralose directly acts on PGP protein, we first examined the effect of sucralose on PGP protein expression. After 24 h of treatment, none of sucralose alone, B[<italic toggle="yes">a</italic>]P alone, and the combined treatment affected PGP protein expression (<xref rid="antioxidants-14-00474-f005" ref-type="fig">Figure 5</xref>A). This result is inconsistent with the enhanced intracellular accumulation and retention of B[<italic toggle="yes">a</italic>]P by sucralose (<xref rid="antioxidants-14-00474-f003" ref-type="fig">Figure 3</xref>), prompting us to investigate whether sucralose can directly interfere with PGP activity.</p><p>We performed virtual docking experiments with sucralose in the PGP transmembrane structural domain. As positive controls, verapamil and quinidine, two known strong inhibitors of PGP, were used for the virtual docking experiments. A complete report of docking positions was provided in <xref rid="app1-antioxidants-14-00474" ref-type="app">Table S1</xref>, along with calculated metrics, including binding affinity and root mean square deviation (RMSD). The molecular docking results showed that the docking energy of PGP with sucralose was the strongest at &#8722;7.35, even exceeding that of verapamil (&#8722;5.31) and quinidine (&#8722;5.51). The bindings posed with the highest binding energy, selected from 50 simulated dockings, were shown in <xref rid="antioxidants-14-00474-f005" ref-type="fig">Figure 5</xref>B, illustrating that sucralose binds more tightly to PGP.</p><p>To experimentally validate the in silico predicted binding interaction between sucralose and P-glycoprotein (PGP), we performed a CETSA assay. The results demonstrated that PGP was more stable and less prone to degradation after binding to sucralose (<xref rid="antioxidants-14-00474-f005" ref-type="fig">Figure 5</xref>C,D). Therefore, these results suggest that sucralose binds to PGP with more affinity, thus leading to the accumulation of B[<italic toggle="yes">a</italic>]P in renal cells.</p></sec><sec id="sec3dot6-antioxidants-14-00474"><title>3.6. Sucralose Combined with B[a]P Inhibits the Expression of PGP and Its Upstream Transcription Factors in the Long Run</title><p>Although none of the treatments within 24 h affected PGP protein expression, after 72 h of treatment, both sucralose alone and B[<italic toggle="yes">a</italic>]P alone reduced PGP protein expression in HK2 cells. Moreover, the combined treatment resulted in a further decrease in PGP protein levels (<xref rid="antioxidants-14-00474-f006" ref-type="fig">Figure 6</xref>A). This observation was further confirmed in the treated mice kidney tissues, as the combined treatment decreased PGP protein expression when compared with B[<italic toggle="yes">a</italic>]P alone (<xref rid="antioxidants-14-00474-f006" ref-type="fig">Figure 6</xref>B,C).</p><p>In a parallel manner, the combined treatment also reduced PGP mRNA expression after 36 h incubation but not after 12 or 24 h (<xref rid="antioxidants-14-00474-f006" ref-type="fig">Figure 6</xref>D), suggesting that the combined treatment might modulate the transcriptional regulation of PGP. To investigate this further, we assessed the expression of upstream transcription factors of PGP, including <italic toggle="yes">PXR</italic>, <italic toggle="yes">NRF2</italic>, and <italic toggle="yes">NF-&#954;B</italic> [<xref rid="B33-antioxidants-14-00474" ref-type="bibr">33</xref>,<xref rid="B34-antioxidants-14-00474" ref-type="bibr">34</xref>,<xref rid="B35-antioxidants-14-00474" ref-type="bibr">35</xref>]. The results demonstrated that sucralose and B[<italic toggle="yes">a</italic>]P co-treatment reduced the mRNA expression of all three transcription factors (<xref rid="antioxidants-14-00474-f006" ref-type="fig">Figure 6</xref>E,G).</p></sec></sec><sec sec-type="discussion" id="sec4-antioxidants-14-00474"><title>4. Discussion</title><p>Artificial sweeteners, introduced to the market as food ingredients in the 19th century [<xref rid="B36-antioxidants-14-00474" ref-type="bibr">36</xref>], were once generally considered safe due to their metabolic inertness. Some studies have shown that long-term consumption of commonly used artificial sweeteners does not cause adverse metabolic effects [<xref rid="B37-antioxidants-14-00474" ref-type="bibr">37</xref>]. However, with the classification of aspartame as a class 2B carcinogen, the safety of artificial sweeteners has triggered a global debate [<xref rid="B38-antioxidants-14-00474" ref-type="bibr">38</xref>]. Although epidemiological data have not found solid evidence of the carcinogenic effects of sucralose [<xref rid="B39-antioxidants-14-00474" ref-type="bibr">39</xref>], some studies have reported its adverse non-tumor effects. For instance, short-term consumption of carbohydrate-containing sucralose has been shown to impair human neuro- and metabolic sensitivity to sugar [<xref rid="B40-antioxidants-14-00474" ref-type="bibr">40</xref>], while long-term sucralose intake has been associated with dysbiosis of the gut microbiota and alterations in glucose and insulin levels in healthy young adults [<xref rid="B41-antioxidants-14-00474" ref-type="bibr">41</xref>].</p><p>B[<italic toggle="yes">a</italic>]P is a class I carcinogen known to damage multiple organs, including the liver, lungs, and kidneys. Its carcinogenic and toxic effects are largely due to its ability to form reactive metabolites that can bind to cellular DNA, leading to mutations and cellular dysfunction. B[<italic toggle="yes">a</italic>]P has been shown to induce ROS, DNA damage and apoptosis via its metabolite benzo[a]pyrene-7,8-dihydrodiol-9,10-epoxide (BPDE), in turn induces hepatic and renal injuries after prolonged exposure [<xref rid="B19-antioxidants-14-00474" ref-type="bibr">19</xref>,<xref rid="B42-antioxidants-14-00474" ref-type="bibr">42</xref>]. While B[<italic toggle="yes">a</italic>]P itself is highly harmful, its toxicity can be exacerbated when combined with other environmental pollutants, leading to more severe adverse effects on human health. Studies have demonstrated that simultaneous exposure to B[<italic toggle="yes">a</italic>]P and phthalates (PAEs), can increase the risk of developing pregnancy-related hypertension [<xref rid="B43-antioxidants-14-00474" ref-type="bibr">43</xref>]. Dibutyl phthalate (DBP), another common phthalate ester, has been shown to exacerbate B[<italic toggle="yes">a</italic>]P-induced renal damage in rats [<xref rid="B44-antioxidants-14-00474" ref-type="bibr">44</xref>]. These results highlight the critical importance of studying the combined exposure to environmental pollutants. Notably, the present study found that sucralose treatment could exacerbate B[<italic toggle="yes">a</italic>]P-induced renal injury in mice and inhibit cell growth in vitro (<xref rid="antioxidants-14-00474-f001" ref-type="fig">Figure 1</xref>). Although both sucralose and B[<italic toggle="yes">a</italic>]P are common environmental exposures, this study, to our knowledge, might be the first report to explore the combined effects of sucralose and B[<italic toggle="yes">a</italic>]P.</p><p>Maintaining oxidative homeostasis is crucial for cell survival, in which antioxidant enzymes may play an important role. It has been reported that B[<italic toggle="yes">a</italic>]P significantly increases ROS production in human hepatocellular carcinoma cells [<xref rid="B36-antioxidants-14-00474" ref-type="bibr">36</xref>] and rat hepatocytes [<xref rid="B45-antioxidants-14-00474" ref-type="bibr">45</xref>]. Among the antioxidant enzymes, superoxide dismutase (SOD) levels are inhibited upon exposure to 10 &#956;M B[<italic toggle="yes">a</italic>]P [<xref rid="B46-antioxidants-14-00474" ref-type="bibr">46</xref>]. Furthermore, B[<italic toggle="yes">a</italic>]P impairs antioxidant capacity by disrupting the activity of SOD3 and GPX4 proteins [<xref rid="B45-antioxidants-14-00474" ref-type="bibr">45</xref>]. Concurred with the previous studies, we confirmed that the combined treatment of sucralose and B[<italic toggle="yes">a</italic>]P increases the ROS level in both HK2 and HEK-293 cells, as well as causes downregulation of several antioxidant genes, including <italic toggle="yes">SOD2</italic>, <italic toggle="yes">CAT</italic>, <italic toggle="yes">GSS</italic>, and <italic toggle="yes">GPX</italic>1 (<xref rid="antioxidants-14-00474-f002" ref-type="fig">Figure 2</xref>). The enhanced inhibitions of both cell growth and antioxidant enzymes by the combined treatment may indicate that sucralose may sensitize B[<italic toggle="yes">a</italic>]P-induced toxicities.</p><p>PGP, an ATP-dependent transmembrane transporter protein, is widely distributed in excretory organs, such as the kidney, liver, and intestines. It plays a crucial role in the excretion of exogenous toxins and drugs, thereby protecting cells from harmful substances, including PAHs [<xref rid="B12-antioxidants-14-00474" ref-type="bibr">12</xref>,<xref rid="B13-antioxidants-14-00474" ref-type="bibr">13</xref>]. Thus, PGP-mediated toxin efflux is regarded as a key component of the detoxification system in the body [<xref rid="B47-antioxidants-14-00474" ref-type="bibr">47</xref>]. Consistent with these findings, we found that sucralose treatment, as well as knockdown of PGP, promotes B[<italic toggle="yes">a</italic>]P accumulation in renal cells (<xref rid="antioxidants-14-00474-f004" ref-type="fig">Figure 4</xref>). These results initially led us to question whether sucralose contributes to the accumulation of B[<italic toggle="yes">a</italic>]P in renal cells by affecting the expression level of PGP. However, the results of Western blotting showed that the combined treatment of sucralose and B[<italic toggle="yes">a</italic>]P for 24 h failed to alter PGP protein levels (<xref rid="antioxidants-14-00474-f005" ref-type="fig">Figure 5</xref>A), suggesting a possible direct action of sucralose on PGP activity. Molecular docking and CETSA assays confirmed that sucralose binds to PGP with high affinity (<xref rid="antioxidants-14-00474-f005" ref-type="fig">Figure 5</xref>), which is consistent with a prior report by Laura Danner et al. [<xref rid="B16-antioxidants-14-00474" ref-type="bibr">16</xref>]. This direct interaction might contribute to the increased intracellular accumulation and retention of B[a]P, which in turn enhanced B[<italic toggle="yes">a</italic>]P-induced cytotoxicity and renal injury.</p><p>Interestingly, after long-term co-treatment (72 h) with both sucralose and B[<italic toggle="yes">a</italic>]P, we observed a significant decrease in PGP protein expression levels (<xref rid="antioxidants-14-00474-f006" ref-type="fig">Figure 6</xref>). Particularly, the combined treatment decreased PGP (<italic toggle="yes">ABCB1</italic>) mRNA expression after 36 h rather than after 12 or 24 h. This inconsistency can be explained by the relatively long protein half-life of PGP (~27 h) [<xref rid="B48-antioxidants-14-00474" ref-type="bibr">48</xref>]. Further mechanistic analyses demonstrated that the combined treatment downregulated the upstream transcriptional regulators of PGP, including <italic toggle="yes">NF-&#954;B</italic>, <italic toggle="yes">NRF2</italic>, and <italic toggle="yes">PXR</italic>, with <italic toggle="yes">NRF2</italic> exhibiting the most consistent pattern of suppression. Collectively, these data support a dual-phase modulation of PGP: (1) The direct binding activity of sucralose to PGP may enable its sensitization effects to enhance B[<italic toggle="yes">a</italic>]P intracellular accumulation and consequent cytotoxicity; (2) The prolonged sucralose treatment (more than 36 h) might impair PGP (<italic toggle="yes">ABCB1</italic>) transcription through the modulation of the upstream transcriptional factors. These two modulatory actions of sucralose against PGP may exacerbate B[<italic toggle="yes">a</italic>]P-induced toxicity. Whether sucralose can affect other xenobiotics through PGP inhibition and sensitize its toxicity warrants further investigation.</p><p>This study, however, has some limitations. First, this study primarily investigated the sub-chronic toxicity of sucralose and B[<italic toggle="yes">a</italic>]P, with a specific focus on the kidneys. Further research is needed to explore the effects of co-exposure to sucralose and B[<italic toggle="yes">a</italic>]P on other organs (e.g., liver, intestines, etc.) over a longer duration to provide a more comprehensive understanding of their biological effects. Second, although the present study has revealed that PGP plays a key role in sucralose-mediated accumulation of B[<italic toggle="yes">a</italic>]P, the precise molecular mechanism underlying PGP&#8217;s involvement, such as how sucralose and B[<italic toggle="yes">a</italic>]P regulate transcription of ABCB1, requires further investigation. Third, it is yet unclear whether co-exposure to sucralose and B[<italic toggle="yes">a</italic>]P can predispose to human disease. Prospective cohort studies might shed light on this essential question. Taken together, a deeper understanding of these mechanisms will allow for a more accurate analysis of the related biological processes and provide a stronger theoretical foundation for future studies and risk assessments.</p></sec><sec sec-type="conclusions" id="sec5-antioxidants-14-00474"><title>5. Conclusions</title><p>In conclusion, the present study demonstrates that the combined treatment with sucralose and B[<italic toggle="yes">a</italic>]P exacerbates renal impairment in mice. Mechanistically, sucralose promotes the accumulation of B[<italic toggle="yes">a</italic>]P within cells by inhibiting the efflux function and expression of PGP. This accumulation, in turn, triggers oxidative stress and inhibits cell growth. Thus, sucralose may enhance the toxic effects of B[<italic toggle="yes">a</italic>]P by interfering with the detoxification protein PGP. These findings highlight the need for further investigations into the combined effects of sucralose and B[<italic toggle="yes">a</italic>]P, given their common exposure and significant public health implications.</p></sec></body><back><ack><title>Acknowledgments</title><p>We are grateful to Tao (Fudan University, Shanghai) for the gift of HEK-293 cells.</p></ack><fn-group><fn><p><bold>Disclaimer/Publisher&#8217;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><app-group><app id="app1-antioxidants-14-00474"><title>Supplementary Materials</title><p>The following supporting information can be downloaded at <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.mdpi.com/article/10.3390/antiox14040474/s1">https://www.mdpi.com/article/10.3390/antiox14040474/s1</uri>, Figure S1: Sucralose combined with B[<italic toggle="yes">a</italic>]p induces subchronic kidney injury. (A) Blood creatinine levels in the indicated treatment groups. (B) Blood urea nitrogen levels in the indicated treatment groups. ns, not significant; Figure S2: Effect of sucralose on HK2 cell proliferation; Table S1: Detailed results of sucralose, verapamil and quinidine docking with PGP simulations.</p><supplementary-material id="antioxidants-14-00474-s001" position="float" content-type="local-data" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="antioxidants-14-00474-s001.zip" position="float" orientation="portrait"/></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>G.-D.L., K.X., X.-Y.H. and J.F. conceived the project. K.X., G.-D.L., X.-Y.H. and J.F. led the project. J.H. and J.F. wrote the first draft. J.F. made important suggestions for animal and in vitro experiments. J.H. completed the data compilation and analysis. J.H., J.F., Y.B., Z.-S.Y. and X.-Y.W. helped with the collection of animal samples. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Department of Laboratory Animal Science of Fudan University (approval number: 202409018S). All experiments were ethically approved by the Department of Laboratory Animal Science, Fudan University (approval number: 202409018S) and performed in accordance with the Association for Assessment and Accreditation of Laboratory Animal Care guidelines.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>All data mentioned in the manuscript can be provided by the corresponding author upon reasonable request.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><ref-list><title>References</title><ref id="B1-antioxidants-14-00474"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stolte</surname><given-names>S.</given-names></name><name name-style="western"><surname>Steudte</surname><given-names>S.</given-names></name><name name-style="western"><surname>Schebb</surname><given-names>N.H.</given-names></name><name name-style="western"><surname>Willenberg</surname><given-names>I.</given-names></name><name name-style="western"><surname>Stepnowski</surname><given-names>P.</given-names></name></person-group><article-title>Ecotoxicity of Artificial Sweeteners and Stevioside</article-title><source>Environ. Int.</source><year>2013</year><volume>60</volume><fpage>123</fpage><lpage>127</lpage><pub-id pub-id-type="doi">10.1016/j.envint.2013.08.010</pub-id><pub-id pub-id-type="pmid">24036324</pub-id></element-citation></ref><ref id="B2-antioxidants-14-00474"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luo</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Li</surname><given-names>C.</given-names></name><name name-style="western"><surname>Xue</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>Q.</given-names></name></person-group><article-title>Ecotoxicity and Environmental Fates of Newly Recognized Contaminants-Artificial Sweeteners: A Review</article-title><source>Sci. Total Environ.</source><year>2019</year><volume>653</volume><fpage>1149</fpage><lpage>1160</lpage><pub-id pub-id-type="doi">10.1016/j.scitotenv.2018.10.445</pub-id><pub-id pub-id-type="pmid">30759555</pub-id></element-citation></ref><ref id="B3-antioxidants-14-00474"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Praveena</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Cheema</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>H.-R.</given-names></name></person-group><article-title>Non-Nutritive Artificial Sweeteners as an Emerging Contaminant in Environment: A Global Review and Risks Perspectives</article-title><source>Ecotoxicol. Environ. Saf.</source><year>2019</year><volume>170</volume><fpage>699</fpage><lpage>707</lpage><pub-id pub-id-type="doi">10.1016/j.ecoenv.2018.12.048</pub-id><pub-id pub-id-type="pmid">30580164</pub-id></element-citation></ref><ref id="B4-antioxidants-14-00474"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ha</surname><given-names>M.-S.</given-names></name><name name-style="western"><surname>Ha</surname><given-names>S.-D.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>S.-H.</given-names></name><name name-style="western"><surname>Bae</surname><given-names>D.-H.</given-names></name></person-group><article-title>Assessment of Korean Consumer Exposure to Sodium Saccharin, Aspartame and Stevioside</article-title><source>Food Addit. Contam. Part A</source><year>2013</year><volume>30</volume><fpage>1238</fpage><lpage>1247</lpage><pub-id pub-id-type="doi">10.1080/19440049.2013.797114</pub-id><pub-id pub-id-type="pmid">23802660</pub-id></element-citation></ref><ref id="B5-antioxidants-14-00474"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tripathi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Khanna</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Das</surname><given-names>M.</given-names></name></person-group><article-title>Usage of Saccharin in Food Products and Its Intake by the Population of Lucknow, India</article-title><source>Food Addit. Contam.</source><year>2006</year><volume>23</volume><fpage>1265</fpage><lpage>1275</lpage><pub-id pub-id-type="doi">10.1080/02652030600944395</pub-id><pub-id pub-id-type="pmid">17118869</pub-id></element-citation></ref><ref id="B6-antioxidants-14-00474"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roberts</surname><given-names>A.</given-names></name><name name-style="western"><surname>Renwick</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>Sims</surname><given-names>J.</given-names></name><name name-style="western"><surname>Snodin</surname><given-names>D.J.</given-names></name></person-group><article-title>Sucralose Metabolism and Pharmacokinetics in Man</article-title><source>Food Chem. Toxicol.</source><year>2000</year><volume>38</volume><issue>(Suppl. 2)</issue><fpage>S31</fpage><lpage>S41</lpage><pub-id pub-id-type="doi">10.1016/S0278-6915(00)00026-0</pub-id><pub-id pub-id-type="pmid">10882816</pub-id></element-citation></ref><ref id="B7-antioxidants-14-00474"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>K&#305;ralan</surname><given-names>S.</given-names></name></person-group><article-title>Phthalate and Polycyclic Aromatic Hydrocarbon Levels in Liquid Ingredients of Packaged Fish Sold in Turkish Markets</article-title><source>J. Oleo Sci.</source><year>2020</year><volume>69</volume><fpage>851</fpage><lpage>858</lpage><pub-id pub-id-type="doi">10.5650/jos.ess20054</pub-id><pub-id pub-id-type="pmid">32641613</pub-id></element-citation></ref><ref id="B8-antioxidants-14-00474"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>G.-Z.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>X.-C.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>S.-H.</given-names></name><name name-style="western"><surname>Qu</surname><given-names>L.-W.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>W.-F.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.-C.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C.</given-names></name><etal/></person-group><article-title>The Aryl Hydrocarbon Receptor Mediates Tobacco-Induced PD-L1 Expression and Is Associated with Response to Immunotherapy</article-title><source>Nat. Commun.</source><year>2019</year><volume>10</volume><fpage>1125</fpage><pub-id pub-id-type="doi">10.1038/s41467-019-08887-7</pub-id><pub-id pub-id-type="pmid">30850589</pub-id><pub-id pub-id-type="pmcid">PMC6408580</pub-id></element-citation></ref><ref id="B9-antioxidants-14-00474"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ji</surname><given-names>W.</given-names></name><name name-style="western"><surname>Song</surname><given-names>L.</given-names></name><name name-style="western"><surname>Dai</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhan</surname><given-names>L.</given-names></name></person-group><article-title>Effects of Exposure to Benzo[a]Pyrene on Metastasis of Breast Cancer Are Mediated through ROS-ERK-MMP9 Axis Signaling</article-title><source>Toxicol. Lett.</source><year>2015</year><volume>234</volume><fpage>201</fpage><lpage>210</lpage><pub-id pub-id-type="doi">10.1016/j.toxlet.2015.02.016</pub-id><pub-id pub-id-type="pmid">25724548</pub-id></element-citation></ref><ref id="B10-antioxidants-14-00474"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Diggs</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Myers</surname><given-names>J.N.</given-names></name><name name-style="western"><surname>Banks</surname><given-names>L.D.</given-names></name><name name-style="western"><surname>Niaz</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Hood</surname><given-names>D.B.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Ramesh</surname><given-names>A.</given-names></name></person-group><article-title>Influence of Dietary Fat Type on Benzo(a)Pyrene [B(a)P] Biotransformation in a B(a)P-Induced Mouse Model of Colon Cancer</article-title><source>J. Nutr. Biochem.</source><year>2013</year><volume>24</volume><fpage>2051</fpage><lpage>2063</lpage><pub-id pub-id-type="doi">10.1016/j.jnutbio.2013.07.006</pub-id><pub-id pub-id-type="pmid">24231098</pub-id><pub-id pub-id-type="pmcid">PMC3904801</pub-id></element-citation></ref><ref id="B11-antioxidants-14-00474"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khattab</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Hussien</surname><given-names>W.F.</given-names></name><name name-style="western"><surname>Raafat</surname><given-names>N.</given-names></name><name name-style="western"><surname>Ahmed Alaa El-Din</surname><given-names>E.</given-names></name></person-group><article-title>Modulatory Effects of Catechin Hydrate on Benzo[a]Pyrene-Induced Nephrotoxicity in Adult Male Albino Rats</article-title><source>Toxicol. Res.</source><year>2021</year><volume>10</volume><fpage>542</fpage><lpage>550</lpage><pub-id pub-id-type="doi">10.1093/toxres/tfab029</pub-id><pub-id pub-id-type="pmid">34141168</pub-id><pub-id pub-id-type="pmcid">PMC8201576</pub-id></element-citation></ref><ref id="B12-antioxidants-14-00474"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tanigawara</surname><given-names>Y.</given-names></name></person-group><article-title>Role of P-Glycoprotein in Drug Disposition</article-title><source>Ther. Drug Monit.</source><year>2000</year><volume>22</volume><fpage>137</fpage><lpage>140</lpage><pub-id pub-id-type="doi">10.1097/00007691-200002000-00029</pub-id><pub-id pub-id-type="pmid">10688277</pub-id></element-citation></ref><ref id="B13-antioxidants-14-00474"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fromm</surname><given-names>M.F.</given-names></name></person-group><article-title>P-Glycoprotein: A Defense Mechanism Limiting Oral Bioavailability and CNS Accumulation of Drugs</article-title><source>Int. J. Clin. Pharmacol. Ther.</source><year>2000</year><volume>38</volume><fpage>69</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.5414/CPP38069</pub-id><pub-id pub-id-type="pmid">10706193</pub-id></element-citation></ref><ref id="B14-antioxidants-14-00474"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fromm</surname><given-names>M.F.</given-names></name></person-group><article-title>Importance of P-Glycoprotein at Blood-Tissue Barriers</article-title><source>Trends Pharmacol. Sci.</source><year>2004</year><volume>25</volume><fpage>423</fpage><lpage>429</lpage><pub-id pub-id-type="doi">10.1016/j.tips.2004.06.002</pub-id><pub-id pub-id-type="pmid">15276711</pub-id></element-citation></ref><ref id="B15-antioxidants-14-00474"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yeh</surname><given-names>G.C.</given-names></name><name name-style="western"><surname>Lopaczynska</surname><given-names>J.</given-names></name><name name-style="western"><surname>Poore</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Phang</surname><given-names>J.M.</given-names></name></person-group><article-title>A New Functional Role for P-Glycoprotein: Efflux Pump for Benzo(Alpha)Pyrene in Human Breast Cancer MCF-7 Cells</article-title><source>Cancer Res.</source><year>1992</year><volume>52</volume><fpage>6692</fpage><lpage>6695</lpage><pub-id pub-id-type="pmid">1358437</pub-id></element-citation></ref><ref id="B16-antioxidants-14-00474"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Danner</surname><given-names>L.</given-names></name><name name-style="western"><surname>Malard</surname><given-names>F.</given-names></name><name name-style="western"><surname>Valdes</surname><given-names>R.</given-names></name><name name-style="western"><surname>Olivier-Van Stichelen</surname><given-names>S.</given-names></name></person-group><article-title>Non-Nutritive Sweeteners Acesulfame Potassium and Sucralose Are Competitive Inhibitors of the Human P-Glycoprotein/Multidrug Resistance Protein 1 (PGP/MDR1)</article-title><source>Nutrients</source><year>2023</year><volume>15</volume><elocation-id>1118</elocation-id><pub-id pub-id-type="doi">10.3390/nu15051118</pub-id><pub-id pub-id-type="pmid">36904118</pub-id><pub-id pub-id-type="pmcid">PMC10005754</pub-id></element-citation></ref><ref id="B17-antioxidants-14-00474"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barangi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mehri</surname><given-names>S.</given-names></name><name name-style="western"><surname>Moosavi</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Hayesd</surname><given-names>A.W.</given-names></name><name name-style="western"><surname>Reiter</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Cardinali</surname><given-names>D.P.</given-names></name><name name-style="western"><surname>Karimi</surname><given-names>G.</given-names></name></person-group><article-title>Melatonin Inhibits Benzo(a)Pyrene-Induced Apoptosis through Activation of the Mir-34a/Sirt1/Autophagy Pathway in Mouse Liver</article-title><source>Ecotoxicol. Environ. Saf.</source><year>2020</year><volume>196</volume><fpage>110556</fpage><pub-id pub-id-type="doi">10.1016/j.ecoenv.2020.110556</pub-id><pub-id pub-id-type="pmid">32247962</pub-id></element-citation></ref><ref id="B18-antioxidants-14-00474"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Labib</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yauk</surname><given-names>C.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>A.</given-names></name><name name-style="western"><surname>Arlt</surname><given-names>V.M.</given-names></name><name name-style="western"><surname>Phillips</surname><given-names>D.H.</given-names></name><name name-style="western"><surname>White</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Halappanavar</surname><given-names>S.</given-names></name></person-group><article-title>Subchronic Oral Exposure to Benzo(a)Pyrene Leads to Distinct Transcriptomic Changes in the Lungs That Are Related to Carcinogenesis</article-title><source>Toxicol. Sci.</source><year>2012</year><volume>129</volume><fpage>213</fpage><lpage>224</lpage><pub-id pub-id-type="doi">10.1093/toxsci/kfs177</pub-id><pub-id pub-id-type="pmid">22610609</pub-id><pub-id pub-id-type="pmcid">PMC3430207</pub-id></element-citation></ref><ref id="B19-antioxidants-14-00474"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ge</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hao</surname><given-names>R.</given-names></name><name name-style="western"><surname>Rong</surname><given-names>X.</given-names></name><name name-style="western"><surname>Dou</surname><given-names>Q.P.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>G.</given-names></name><name name-style="western"><surname>Li</surname><given-names>F.</given-names></name><name name-style="western"><surname>Li</surname><given-names>D.</given-names></name></person-group><article-title>Secoisolariciresinol Diglucoside Mitigates Benzo[a]Pyrene-Induced Liver and Kidney Toxicity in Mice via miR-101a/MKP-1-Mediated P38 and ERK Pathway</article-title><source>Food Chem. Toxicol.</source><year>2022</year><volume>159</volume><fpage>112733</fpage><pub-id pub-id-type="doi">10.1016/j.fct.2021.112733</pub-id><pub-id pub-id-type="pmid">34856318</pub-id></element-citation></ref><ref id="B20-antioxidants-14-00474"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Delgado-Roche</surname><given-names>L.</given-names></name><name name-style="western"><surname>Rodeiro</surname><given-names>I.</given-names></name><name name-style="western"><surname>Riera</surname><given-names>M.</given-names></name><name name-style="western"><surname>Herrera</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Venturi</surname><given-names>I.</given-names></name><name name-style="western"><surname>Hern&#225;ndez</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Fern&#225;ndez</surname><given-names>G.</given-names></name><name name-style="western"><surname>P&#233;rez</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>Rodriguez</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Fern&#225;ndez</surname><given-names>M.D.</given-names></name><etal/></person-group><article-title>Chemoprotective Effects of Ulva Lactuca (Green Seaweed) Aqueous-Ethanolic Extract against Subchronic Exposure to Benzo(a)Pyrene by CYP1A1 Inhibition in Mice</article-title><source>Phytother. Res.</source><year>2019</year><volume>33</volume><fpage>958</fpage><lpage>967</lpage><pub-id pub-id-type="doi">10.1002/ptr.6289</pub-id><pub-id pub-id-type="pmid">30729585</pub-id></element-citation></ref><ref id="B21-antioxidants-14-00474"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>S.</given-names></name><name name-style="western"><surname>Long</surname><given-names>C.</given-names></name><name name-style="western"><surname>Li</surname><given-names>G.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Y.</given-names></name></person-group><article-title>Urinary Monohydroxylated Polycyclic Aromatic Hydrocarbons in the General Population from 26 Provincial Capital Cities in China: Levels, Influencing Factors, and Health Risks</article-title><source>Environ. Int.</source><year>2022</year><volume>160</volume><fpage>107074</fpage><pub-id pub-id-type="doi">10.1016/j.envint.2021.107074</pub-id><pub-id pub-id-type="pmid">34995968</pub-id></element-citation></ref><ref id="B22-antioxidants-14-00474"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zani</surname><given-names>F.</given-names></name><name name-style="western"><surname>Blagih</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gruber</surname><given-names>T.</given-names></name><name name-style="western"><surname>Buck</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>N.</given-names></name><name name-style="western"><surname>Hennequart</surname><given-names>M.</given-names></name><name name-style="western"><surname>Newell</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>Pilley</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Soro-Barrio</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kelly</surname><given-names>G.</given-names></name><etal/></person-group><article-title>The Dietary Sweetener Sucralose Is a Negative Modulator of T Cell-Mediated Responses</article-title><source>Nature</source><year>2023</year><volume>615</volume><fpage>705</fpage><lpage>711</lpage><pub-id pub-id-type="doi">10.1038/s41586-023-05801-6</pub-id><pub-id pub-id-type="pmid">36922598</pub-id><pub-id pub-id-type="pmcid">PMC10033444</pub-id></element-citation></ref><ref id="B23-antioxidants-14-00474"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Feng</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bin</surname><given-names>J.-L.</given-names></name><name name-style="western"><surname>Liao</surname><given-names>X.-W.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>P.-Z.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>G.-Z.</given-names></name><name name-style="western"><surname>Cui</surname><given-names>Q.-R.</given-names></name><name name-style="western"><surname>Dan</surname><given-names>Y.Y.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>G.-H.</given-names></name><etal/></person-group><article-title>The Prognostic Role of ACSL4 in Postoperative Adjuvant TACE-Treated HCC: Implications for Therapeutic Response and Mechanistic Insights</article-title><source>J. Exp. Clin. Cancer Res.</source><year>2024</year><volume>43</volume><fpage>306</fpage><pub-id pub-id-type="doi">10.1186/s13046-024-03222-5</pub-id><pub-id pub-id-type="pmid">39563427</pub-id><pub-id pub-id-type="pmcid">PMC11575417</pub-id></element-citation></ref><ref id="B24-antioxidants-14-00474"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Huo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>K.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>F.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>Z.</given-names></name></person-group><article-title>Tubular p53 regulates multiple genes to mediate AKI</article-title><source>J. Am. Soc. Nephrol.</source><year>2014</year><volume>25</volume><fpage>2278</fpage><lpage>2289</lpage><pub-id pub-id-type="doi">10.1681/ASN.2013080902</pub-id><pub-id pub-id-type="pmid">24700871</pub-id><pub-id pub-id-type="pmcid">PMC4178437</pub-id></element-citation></ref><ref id="B25-antioxidants-14-00474"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nosol</surname><given-names>K.</given-names></name><name name-style="western"><surname>Romane</surname><given-names>K.</given-names></name><name name-style="western"><surname>Irobalieva</surname><given-names>R.N.</given-names></name><name name-style="western"><surname>Alam</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kowal</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fujita</surname><given-names>N.</given-names></name><name name-style="western"><surname>Locher</surname><given-names>K.P.</given-names></name></person-group><article-title>Cryo-EM Structures Reveal Distinct Mechanisms of Inhibition of the Human Multidrug Transporter ABCB1</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2020</year><volume>117</volume><fpage>26245</fpage><lpage>26253</lpage><pub-id pub-id-type="doi">10.1073/pnas.2010264117</pub-id><pub-id pub-id-type="pmid">33020312</pub-id><pub-id pub-id-type="pmcid">PMC7585025</pub-id></element-citation></ref><ref id="B26-antioxidants-14-00474"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eberhardt</surname><given-names>J.</given-names></name><name name-style="western"><surname>Santos-Martins</surname><given-names>D.</given-names></name><name name-style="western"><surname>Tillack</surname><given-names>A.F.</given-names></name><name name-style="western"><surname>Forli</surname><given-names>S.</given-names></name></person-group><article-title>AutoDock Vina 1.2.0: New Docking Methods, Expanded Force Field, and Python Bindings</article-title><source>J. Chem. Inf. Model.</source><year>2021</year><volume>61</volume><fpage>3891</fpage><lpage>3898</lpage><pub-id pub-id-type="doi">10.1021/acs.jcim.1c00203</pub-id><pub-id pub-id-type="pmid">34278794</pub-id><pub-id pub-id-type="pmcid">PMC10683950</pub-id></element-citation></ref><ref id="B27-antioxidants-14-00474"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ravindranath</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Forli</surname><given-names>S.</given-names></name><name name-style="western"><surname>Goodsell</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Olson</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Sanner</surname><given-names>M.F.</given-names></name></person-group><article-title>AutoDockFR: Advances in Protein-Ligand Docking with Explicitly Specified Binding Site Flexibility</article-title><source>PLoS Comput. Biol.</source><year>2015</year><volume>11</volume><elocation-id>e1004586</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pcbi.1004586</pub-id><pub-id pub-id-type="pmid">26629955</pub-id><pub-id pub-id-type="pmcid">PMC4667975</pub-id></element-citation></ref><ref id="B28-antioxidants-14-00474"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lomize</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Pogozheva</surname><given-names>I.D.</given-names></name><name name-style="western"><surname>Joo</surname><given-names>H.</given-names></name><name name-style="western"><surname>Mosberg</surname><given-names>H.I.</given-names></name><name name-style="western"><surname>Lomize</surname><given-names>A.L.</given-names></name></person-group><article-title>OPM Database and PPM Web Server: Resources for Positioning of Proteins in Membranes</article-title><source>Nucleic Acids Res.</source><year>2012</year><volume>40</volume><fpage>D370</fpage><lpage>D376</lpage><pub-id pub-id-type="doi">10.1093/nar/gkr703</pub-id><pub-id pub-id-type="pmid">21890895</pub-id><pub-id pub-id-type="pmcid">PMC3245162</pub-id></element-citation></ref><ref id="B29-antioxidants-14-00474"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sylvetsky</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Bauman</surname><given-names>V.</given-names></name><name name-style="western"><surname>Blau</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Garraffo</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Walter</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Rother</surname><given-names>K.I.</given-names></name></person-group><article-title>Plasma Concentrations of Sucralose in Children and Adults</article-title><source>Toxicol. Environ. Chem.</source><year>2017</year><volume>99</volume><fpage>535</fpage><lpage>542</lpage><pub-id pub-id-type="doi">10.1080/02772248.2016.1234754</pub-id><pub-id pub-id-type="pmid">28775393</pub-id><pub-id pub-id-type="pmcid">PMC5536901</pub-id></element-citation></ref><ref id="B30-antioxidants-14-00474"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>G.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xiong</surname><given-names>W.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>J.</given-names></name></person-group><article-title>BaP-Induced DNA Damage Initiated P53-Independent Necroptosis via the Mitochondrial Pathway Involving Bax and Bcl-2</article-title><source>Hum. Exp. Toxicol.</source><year>2013</year><volume>32</volume><fpage>1245</fpage><lpage>1257</lpage><pub-id pub-id-type="doi">10.1177/0960327113488613</pub-id><pub-id pub-id-type="pmid">23703817</pub-id></element-citation></ref><ref id="B31-antioxidants-14-00474"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>T.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Mo</surname><given-names>X.</given-names></name><name name-style="western"><surname>Song</surname><given-names>N.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zouboulis</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ju</surname><given-names>Q.</given-names></name></person-group><article-title>Benzo(a)Pyrene Induces Interleukin (IL)-6 Production and Reduces Lipid Synthesis in Human SZ95 Sebocytes via the Aryl Hydrocarbon Receptor Signaling Pathway</article-title><source>Environ. Toxicol. Pharmacol.</source><year>2016</year><volume>43</volume><fpage>54</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1016/j.etap.2016.02.011</pub-id><pub-id pub-id-type="pmid">26963242</pub-id></element-citation></ref><ref id="B32-antioxidants-14-00474"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Holme</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Gorria</surname><given-names>M.</given-names></name><name name-style="western"><surname>Arlt</surname><given-names>V.M.</given-names></name><name name-style="western"><surname>Ovreb&#248;</surname><given-names>S.</given-names></name><name name-style="western"><surname>Solhaug</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tekpli</surname><given-names>X.</given-names></name><name name-style="western"><surname>Landvik</surname><given-names>N.E.</given-names></name><name name-style="western"><surname>Huc</surname><given-names>L.</given-names></name><name name-style="western"><surname>Fardel</surname><given-names>O.</given-names></name><name name-style="western"><surname>Lagadic-Gossmann</surname><given-names>D.</given-names></name></person-group><article-title>Different Mechanisms Involved in Apoptosis Following Exposure to Benzo[a]Pyrene in F258 and Hepa1c1c7 Cells</article-title><source>Chem. Biol. Interact.</source><year>2007</year><volume>167</volume><fpage>41</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1016/j.cbi.2007.01.008</pub-id><pub-id pub-id-type="pmid">17289009</pub-id></element-citation></ref><ref id="B33-antioxidants-14-00474"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>H.G.</given-names></name><name name-style="western"><surname>Hien</surname><given-names>T.T.</given-names></name><name name-style="western"><surname>Han</surname><given-names>E.H.</given-names></name><name name-style="western"><surname>Hwang</surname><given-names>Y.P.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>K.W.</given-names></name><name name-style="western"><surname>Kwon</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>B.-H.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Song</surname><given-names>G.Y.</given-names></name><etal/></person-group><article-title>Metformin Inhibits P-Glycoprotein Expression via the NF-&#954;B Pathway and CRE Transcriptional Activity through AMPK Activation</article-title><source>Br. J. Pharmacol.</source><year>2011</year><volume>162</volume><fpage>1096</fpage><lpage>1108</lpage><pub-id pub-id-type="doi">10.1111/j.1476-5381.2010.01101.x</pub-id><pub-id pub-id-type="pmid">21054339</pub-id><pub-id pub-id-type="pmcid">PMC3051382</pub-id></element-citation></ref><ref id="B34-antioxidants-14-00474"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bharathiraja</surname><given-names>P.</given-names></name><name name-style="western"><surname>Baskar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Prasad</surname><given-names>N.R.</given-names></name></person-group><article-title>Solasodine Downregulates ABCB1 Overexpression in Multidrug Resistant Cancer Cells via Inhibiting Nrf2/Keap1 Signaling Pathway</article-title><source>J. Cell. Biochem.</source><year>2025</year><volume>126</volume><elocation-id>e30674</elocation-id><pub-id pub-id-type="doi">10.1002/jcb.30674</pub-id><pub-id pub-id-type="pmid">39535293</pub-id></element-citation></ref><ref id="B35-antioxidants-14-00474"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ji</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ni</surname><given-names>S.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Tian</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name></person-group><article-title>Antimalarial Activity and Sensitization of Chrysosplenetin against Artemisinin-Resistant Genotype Plasmodium Berghei K173 Potentially via Dual-Mechanism of Maintaining Host P-Glycoprotein Homeostasis Mediated by NF-&#954;B P52 or PXR/CAR Signaling Pathways and Regulating Heme/Haemozoin Metabolism</article-title><source>Phytother. Res.</source><year>2023</year><volume>37</volume><fpage>2939</fpage><lpage>2956</lpage><pub-id pub-id-type="doi">10.1002/ptr.7789</pub-id><pub-id pub-id-type="pmid">36938853</pub-id></element-citation></ref><ref id="B36-antioxidants-14-00474"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shah</surname><given-names>S.I.A.</given-names></name><name name-style="western"><surname>Nawaz</surname><given-names>H.</given-names></name><name name-style="western"><surname>Nadeem</surname><given-names>N.</given-names></name></person-group><article-title>Historical and Current Perspectives on the Human Consumption of Non-Nutritive Sweeteners (NNS)</article-title><source>J. Akhtar Saeed Med. Dent. Coll.</source><year>2023</year><volume>5</volume><fpage>243</fpage><lpage>249</lpage><pub-id pub-id-type="doi">10.51127/JAMDC5I4RA01</pub-id></element-citation></ref><ref id="B37-antioxidants-14-00474"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rathaus</surname><given-names>M.</given-names></name><name name-style="western"><surname>Azem</surname><given-names>L.</given-names></name><name name-style="western"><surname>Livne</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ron</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ron</surname><given-names>I.</given-names></name><name name-style="western"><surname>Hadar</surname><given-names>R.</given-names></name><name name-style="western"><surname>Efroni</surname><given-names>G.</given-names></name><name name-style="western"><surname>Amir</surname><given-names>A.</given-names></name><name name-style="western"><surname>Braun</surname><given-names>T.</given-names></name><name name-style="western"><surname>Haberman</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Long-Term Metabolic Effects of Non-Nutritive Sweeteners</article-title><source>Mol. Metab.</source><year>2024</year><volume>88</volume><fpage>101985</fpage><pub-id pub-id-type="doi">10.1016/j.molmet.2024.101985</pub-id><pub-id pub-id-type="pmid">38977130</pub-id><pub-id pub-id-type="pmcid">PMC11347859</pub-id></element-citation></ref><ref id="B38-antioxidants-14-00474"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Riboli</surname><given-names>E.</given-names></name><name name-style="western"><surname>Beland</surname><given-names>F.A.</given-names></name><name name-style="western"><surname>Lachenmeier</surname><given-names>D.W.</given-names></name><name name-style="western"><surname>Marques</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Phillips</surname><given-names>D.H.</given-names></name><name name-style="western"><surname>Schernhammer</surname><given-names>E.</given-names></name><name name-style="western"><surname>Afghan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Assun&#231;&#227;o</surname><given-names>R.</given-names></name><name name-style="western"><surname>Caderni</surname><given-names>G.</given-names></name><name name-style="western"><surname>Corton</surname><given-names>J.C.</given-names></name><etal/></person-group><article-title>Carcinogenicity of Aspartame, Methyleugenol, and Isoeugenol</article-title><source>Lancet Oncol.</source><year>2023</year><volume>24</volume><fpage>848</fpage><lpage>850</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(23)00341-8</pub-id><pub-id pub-id-type="pmid">37454664</pub-id></element-citation></ref><ref id="B39-antioxidants-14-00474"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Debras</surname><given-names>C.</given-names></name><name name-style="western"><surname>Chazelas</surname><given-names>E.</given-names></name><name name-style="western"><surname>Srour</surname><given-names>B.</given-names></name><name name-style="western"><surname>Druesne-Pecollo</surname><given-names>N.</given-names></name><name name-style="western"><surname>Esseddik</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Szabo de Edelenyi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Aga&#235;sse</surname><given-names>C.</given-names></name><name name-style="western"><surname>De Sa</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lutchia</surname><given-names>R.</given-names></name><name name-style="western"><surname>Gigandet</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Artificial Sweeteners and Cancer Risk: Results from the NutriNet-Sant&#233; Population-Based Cohort Study</article-title><source>PLoS Med.</source><year>2022</year><volume>19</volume><elocation-id>e1003950</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pmed.1003950</pub-id><pub-id pub-id-type="pmid">35324894</pub-id><pub-id pub-id-type="pmcid">PMC8946744</pub-id></element-citation></ref><ref id="B40-antioxidants-14-00474"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dalenberg</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>B.P.</given-names></name><name name-style="western"><surname>Denis</surname><given-names>R.</given-names></name><name name-style="western"><surname>Veldhuizen</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Nakamura</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Vinke</surname><given-names>P.C.</given-names></name><name name-style="western"><surname>Luquet</surname><given-names>S.</given-names></name><name name-style="western"><surname>Small</surname><given-names>D.M.</given-names></name></person-group><article-title>Short-Term Consumption of Sucralose with, but Not without, Carbohydrate Impairs Neural and Metabolic Sensitivity to Sugar in Humans</article-title><source>Cell Metab.</source><year>2020</year><volume>31</volume><fpage>493</fpage><lpage>502.e7</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2020.01.014</pub-id><pub-id pub-id-type="pmid">32130881</pub-id><pub-id pub-id-type="pmcid">PMC7784207</pub-id></element-citation></ref><ref id="B41-antioxidants-14-00474"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>M&#233;ndez-Garc&#237;a</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Bueno-Hern&#225;ndez</surname><given-names>N.</given-names></name><name name-style="western"><surname>Cid-Soto</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>De Le&#243;n</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Mendoza-Mart&#237;nez</surname><given-names>V.M.</given-names></name><name name-style="western"><surname>Espinosa-Flores</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Carrero-Aguirre</surname><given-names>M.</given-names></name><name name-style="western"><surname>Esquivel-Vel&#225;zquez</surname><given-names>M.</given-names></name><name name-style="western"><surname>Le&#243;n-Hern&#225;ndez</surname><given-names>M.</given-names></name><name name-style="western"><surname>Viurcos-Sanabria</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Ten-Week Sucralose Consumption Induces Gut Dysbiosis and Altered Glucose and Insulin Levels in Healthy Young Adults</article-title><source>Microorganisms</source><year>2022</year><volume>10</volume><elocation-id>434</elocation-id><pub-id pub-id-type="doi">10.3390/microorganisms10020434</pub-id><pub-id pub-id-type="pmid">35208888</pub-id><pub-id pub-id-type="pmcid">PMC8880058</pub-id></element-citation></ref><ref id="B42-antioxidants-14-00474"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>John</surname><given-names>A.</given-names></name><name name-style="western"><surname>Raza</surname><given-names>H.</given-names></name></person-group><article-title>Azadirachtin Attenuates Carcinogen Benzo(a) Pyrene-Induced DNA Damage, Cell Cycle Arrest, Apoptosis, Inflammatory, Metabolic, and Oxidative Stress in HepG2 Cells</article-title><source>Antioxidants</source><year>2023</year><volume>12</volume><elocation-id>2001</elocation-id><pub-id pub-id-type="doi">10.3390/antiox12112001</pub-id><pub-id pub-id-type="pmid">38001854</pub-id><pub-id pub-id-type="pmcid">PMC10669168</pub-id></element-citation></ref><ref id="B43-antioxidants-14-00474"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Na</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Jia</surname><given-names>X.</given-names></name><name name-style="western"><surname>Ren</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Han</surname><given-names>B.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>N.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z.</given-names></name><etal/></person-group><article-title>Co-Exposure to Phthalates and Polycyclic Aromatic Hydrocarbons and the Risk of Gestational Hypertension in Chinese Women</article-title><source>Environ. Int.</source><year>2024</year><volume>185</volume><fpage>108562</fpage><pub-id pub-id-type="doi">10.1016/j.envint.2024.108562</pub-id><pub-id pub-id-type="pmid">38460239</pub-id></element-citation></ref><ref id="B44-antioxidants-14-00474"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Song</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>W.</given-names></name><name name-style="western"><surname>Cen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>You</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>G.</given-names></name></person-group><article-title>DBP and BaP Co-Exposure Induces Kidney Injury via Promoting Pyroptosis of Renal Tubular Epithelial Cells in Rats</article-title><source>Chemosphere</source><year>2023</year><volume>314</volume><fpage>137714</fpage><pub-id pub-id-type="doi">10.1016/j.chemosphere.2022.137714</pub-id><pub-id pub-id-type="pmid">36592837</pub-id></element-citation></ref><ref id="B45-antioxidants-14-00474"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tao</surname><given-names>C.</given-names></name><name name-style="western"><surname>Tong</surname><given-names>J.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>T.</given-names></name></person-group><article-title>Uncovering SOD3 and GPX4 as New Targets of Benzo[&#945;]Pyrene-Induced Hepatotoxicity through Metabolomics and Chemical Proteomics</article-title><source>Redox Biol.</source><year>2023</year><volume>67</volume><elocation-id>102930</elocation-id><pub-id pub-id-type="doi">10.1016/j.redox.2023.102930</pub-id><pub-id pub-id-type="pmid">37847980</pub-id><pub-id pub-id-type="pmcid">PMC10585396</pub-id></element-citation></ref><ref id="B46-antioxidants-14-00474"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Min</surname><given-names>L.</given-names></name><name name-style="western"><surname>He</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>F.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>H.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>M.</given-names></name></person-group><article-title>Comparative Proteomic Analysis of Cellular Response of Human Airway Epithelial Cells (A549) to Benzo(a)Pyrene</article-title><source>Toxicol. Mech. Methods</source><year>2011</year><volume>21</volume><fpage>374</fpage><lpage>382</lpage><pub-id pub-id-type="doi">10.3109/15376516.2010.551555</pub-id><pub-id pub-id-type="pmid">21417634</pub-id></element-citation></ref><ref id="B47-antioxidants-14-00474"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Lange</surname><given-names>E.C.M.</given-names></name></person-group><article-title>Potential Role of ABC Transporters as a Detoxification System at the Blood-CSF Barrier</article-title><source>Adv. Drug Deliv. Rev.</source><year>2004</year><volume>56</volume><fpage>1793</fpage><lpage>1809</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2004.07.009</pub-id><pub-id pub-id-type="pmid">15381334</pub-id></element-citation></ref><ref id="B48-antioxidants-14-00474"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Katayama</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kapoor</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ohnuma</surname><given-names>S.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>A.</given-names></name><name name-style="western"><surname>Swaim</surname><given-names>W.</given-names></name><name name-style="western"><surname>Ambudkar</surname><given-names>I.S.</given-names></name><name name-style="western"><surname>Ambudkar</surname><given-names>S.V.</given-names></name></person-group><article-title>Revealing the Fate of Cell Surface Human P-Glycoprotein (ABCB1): The Lysosomal Degradation Pathway</article-title><source>Biochim. Biophys. Acta</source><year>2015</year><volume>1853</volume><fpage>2361</fpage><lpage>2370</lpage><pub-id pub-id-type="doi">10.1016/j.bbamcr.2015.06.001</pub-id><pub-id pub-id-type="pmid">26057472</pub-id><pub-id pub-id-type="pmcid">PMC4558211</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="antioxidants-14-00474-f001" orientation="portrait"><label>Figure 1</label><caption><p>Subchronic treatment of sucralose enhanced B[<italic toggle="yes">a</italic>]P-induced kidney injury. Male C57BL/6N mice were treated with the indicated treatments for 90 days as in Material and Methods. The kidney injuries were monitored through quantification of (<bold>A</bold>) serum creatinine levels and (<bold>B</bold>) serum urea nitrogen levels or by (<bold>C</bold>) H&amp;E histopathological examinations. Red triangles, atrophic flattening of renal proximal tubules. Black arrow, glomerular atrophy, and deformation. Green arrow: Renal tubular epithelial cell detachment. Scale bar: 100 &#181;m. (<bold>D</bold>) Tubular injuries were scored (<italic toggle="yes">n</italic> = 5) and then summarized as described in <xref rid="sec2dot5-antioxidants-14-00474" ref-type="sec">Section 2.5</xref>. * <italic toggle="yes">p</italic> &lt; 0.05; ** <italic toggle="yes">p</italic> &lt; 0.01; **** <italic toggle="yes">p</italic> &lt; 0.0001; ns, not significant.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="antioxidants-14-00474-g001.jpg"/></fig><fig position="float" id="antioxidants-14-00474-f002" orientation="portrait"><label>Figure 2</label><caption><p>Sucralose could exacerbate B[<italic toggle="yes">a</italic>]P-induced cell growth inhibition and ROS production. HK2 (<bold>A</bold>) and HEK-293 cells (<bold>B</bold>) were exposed to sucralose (10 &#956;M), B[<italic toggle="yes">a</italic>]P (20 &#956;M), or combination for 24 or 72 h. The cell growth was then determined. (<bold>C</bold>) ROS levels in HK2 cells, as indicated by DCFDA fluorescence, were captured by fluorescent microscopy. Scale bar: 200 &#181;m. (<bold>D</bold>) Total ROS levels in HK2 and HEK-293 cells after indicated treatments were determined by flow cytometry, and positive group refers to Rosup, a compound mixture that induces ROS. (<bold>E</bold>) Mitochondrial ROS levels in HK2 and HEK-293 cells with indicated treatments, positive group refers to mSoxUp, a compound mixture that induces superoxide formation in mitochondria. (<bold>F</bold>) Expression levels of <italic toggle="yes">SOD2</italic>, <italic toggle="yes">CAT</italic>, <italic toggle="yes">GSS</italic>, and <italic toggle="yes">GPX1</italic> genes in HK2 and HEK-293 cells were examined by qRT-PCR after indicated treatments. Each experiment was performed independently three times. * <italic toggle="yes">p</italic> &lt; 0.05; ** <italic toggle="yes">p</italic> &lt; 0.01; *** <italic toggle="yes">p</italic> &lt; 0.001; **** <italic toggle="yes">p</italic> &lt; 0.0001; ns, not significant.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="antioxidants-14-00474-g002.jpg"/></fig><fig position="float" id="antioxidants-14-00474-f003" orientation="portrait"><label>Figure 3</label><caption><p>Sucralose enhanced the intracellular accumulation and retention of B[<italic toggle="yes">a</italic>]P. HK2 (<bold>A</bold>) and HEK-293 cells (<bold>B</bold>) were treated with B[<italic toggle="yes">a</italic>]P in the presence or absence of sucralose (10 &#956;M). The intracellular B[<italic toggle="yes">a</italic>] concentration was then determined by flow cytometry in a time course, and the relative fluorescence values normalized to the 2 h fluorescence value of the B[<italic toggle="yes">a</italic>]P group (set as 100%). (<bold>C</bold>,<bold>D</bold>) HK2 (<bold>C</bold>) and HEK-293 cells (<bold>D</bold>) were treated with B[<italic toggle="yes">a</italic>]P alone for 12 h. After replacement with the sucralose-containing fresh medium, the retention of B[<italic toggle="yes">a</italic>]P was determined in 2 h-interval. Each experiment was performed independently three times. **** <italic toggle="yes">p</italic> &lt; 0.0001.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="antioxidants-14-00474-g003.jpg"/></fig><fig position="float" id="antioxidants-14-00474-f004" orientation="portrait"><label>Figure 4</label><caption><p>PGP plays a critical role in sucralose-induced accumulation of B[<italic toggle="yes">a</italic>]P. (<bold>A</bold>) HK2 cells were treated with PGP siRNA, and then the protein level of PGP was detected. (<bold>B</bold>,<bold>C</bold>) Effect of knockdown of PGP alone on B[<italic toggle="yes">a</italic>]P accumulation (<bold>B</bold>) and retention (<bold>C</bold>) in HK2 cells. (<bold>D</bold>,<bold>E</bold>) Effect of knockdown of PGP on sucralose-induced B[<italic toggle="yes">a</italic>]P accumulation (<bold>D</bold>) and retention (<bold>E</bold>) in HK2 cells. Each experiment was performed independently three times. **** <italic toggle="yes">p</italic> &lt; 0.0001.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="antioxidants-14-00474-g004.jpg"/></fig><fig position="float" id="antioxidants-14-00474-f005" orientation="portrait"><label>Figure 5</label><caption><p>Sucralose directly binds to PGP. (<bold>A</bold>,<bold>B</bold>) Expression of PGP protein in HK2 cells after the indicated treatments for 24 h. (<bold>B</bold>) Optimal binding postures of sucralose to PGP, together with verapamil and quinidine as positive controls. (<bold>C</bold>,<bold>D</bold>) CETSA experiments were performed to confirm the interaction between PGP protein and sucralose or verapamil (<bold>C</bold>). The quantitative results were summarized in panel D. Each experiment was performed independently three times. **** <italic toggle="yes">p</italic> &lt; 0.0001; ns, not significant.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="antioxidants-14-00474-g005.jpg"/></fig><fig position="float" id="antioxidants-14-00474-f006" orientation="portrait"><label>Figure 6</label><caption><p>The combined treatment inhibited PGP transcription in the long run. (<bold>A</bold>) The expression of PGP protein was determined in HK2 after the indicated treatments for 72 h. (<bold>B</bold>,<bold>C</bold>) PGP expression in mouse kidney tissues was analyzed by IHC. Representative images (<bold>B</bold>) and quantitative analysis (<bold>C</bold>) were shown. (<bold>D</bold>) PGP (<italic toggle="yes">ABCB1</italic>) mRNA levels were determined by qRT-PCR in HK2 cells after 12 h, 24 h, and 36 h of different treatments. (<bold>E</bold>&#8211;<bold>G</bold>) Upstream transcription factors <italic toggle="yes">PXR</italic> (<bold>E</bold>), <italic toggle="yes">NF-&#954;B</italic> (<bold>F</bold>), and <italic toggle="yes">NRF2</italic> (<bold>G</bold>) mRNA levels were determined in HK2 cells after 36 h of the indicted treatments. Each experiment was performed independently three times. * <italic toggle="yes">p</italic> &lt; 0.05; *** <italic toggle="yes">p</italic> &lt; 0.001; **** <italic toggle="yes">p</italic> &lt; 0.0001, ns, not significant. Scale bar: 100 &#181;m.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="antioxidants-14-00474-g006.jpg"/></fig><table-wrap position="float" id="antioxidants-14-00474-t001" orientation="portrait"><object-id pub-id-type="pii">antioxidants-14-00474-t001_Table 1</object-id><label>Table 1</label><caption><p>Sequences of si-RNAs.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Name</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Sense (5&#8242; to 3&#8242;)</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">NC-si</td><td align="center" valign="middle" rowspan="1" colspan="1">UUCUCCGAACGUGUCACGU</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">PGP-si1</td><td align="center" valign="middle" rowspan="1" colspan="1">CAAUGUUUCGCUAUUCAAA</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">PGP-si2</td><td align="center" valign="middle" rowspan="1" colspan="1">GGAGGAGCAAAGAAGAAGA</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PGP-si3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GGAAUGUUCUUUCAGUCAA</td></tr></tbody></table></table-wrap><table-wrap position="float" id="antioxidants-14-00474-t002" orientation="portrait"><object-id pub-id-type="pii">antioxidants-14-00474-t002_Table 2</object-id><label>Table 2</label><caption><p>Information of primers.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Genes</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Accession Number</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Forward Primer Sequence</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Reverse Primer Sequence</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">ABCB1</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="NM_001348946">NM_001348946</ext-link></td><td align="center" valign="middle" rowspan="1" colspan="1">GTCCCAGGAGCCCATCCT</td><td align="center" valign="middle" rowspan="1" colspan="1">CCCGGCTGTTGTCTCCATA</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">NRF2</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="NM_006164">NM_006164</ext-link></td><td align="center" valign="middle" rowspan="1" colspan="1">TCAGCGACGGAAAGAGTATGA</td><td align="center" valign="middle" rowspan="1" colspan="1">CCACTGGTTTCTGACTGGATGT</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">NF-&#954;B</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="NM_003998">NM_003998</ext-link></td><td align="center" valign="middle" rowspan="1" colspan="1">AACAGAGAGGATTTCGTTTCCG</td><td align="center" valign="middle" rowspan="1" colspan="1">TTTGACCTGAGGGTAAGACTTCT</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">PXR</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="NM_003889">NM_003889</ext-link></td><td align="center" valign="middle" rowspan="1" colspan="1">AAGCCCAGTGTCAACGCAG</td><td align="center" valign="middle" rowspan="1" colspan="1">GGGTCTTCCGGGTGATCTC</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">SOD2</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="NM_001322816">NM_001322816</ext-link></td><td align="center" valign="middle" rowspan="1" colspan="1">GCTCCGGTTTTGGGGTATCTG</td><td align="center" valign="middle" rowspan="1" colspan="1">GCGTTGATGTGAGGTTCCAG</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">CAT</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="NM_001752">NM_001752</ext-link></td><td align="center" valign="middle" rowspan="1" colspan="1">TGGAGCTGGTAACCCAGTAGG</td><td align="center" valign="middle" rowspan="1" colspan="1">CCTTTGCCTTGGAGTATTTGGTA</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">GSS</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="NM_000178">NM_000178</ext-link></td><td align="center" valign="middle" rowspan="1" colspan="1">GGGAGCCTCTTGCAGGATAAA</td><td align="center" valign="middle" rowspan="1" colspan="1">GAATGGGGCATAGCTCACCAC</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">GPX1</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="NM_000581">NM_000581</ext-link></td><td align="center" valign="middle" rowspan="1" colspan="1">CAGTCGGTGTATGCCTTCTCG</td><td align="center" valign="middle" rowspan="1" colspan="1">GAGGGACGCCACATTCTCG</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">ACTB</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="NM_001101">NM_001101</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GGACTTCGAGCAAGAGATGG</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AGCACTGTGTTGGCGTACAG</td></tr></tbody></table></table-wrap></floats-group></article></pmc-articleset>